Management of patients with NTRK fusion-positive thyroid cancer.
APA
Wirth LJ (2024). Management of patients with NTRK fusion-positive thyroid cancer.. Clinical advances in hematology & oncology : H&O, 22 Suppl 5(6), 9-15.
MLA
Wirth LJ. "Management of patients with NTRK fusion-positive thyroid cancer.." Clinical advances in hematology & oncology : H&O, vol. 22 Suppl 5, no. 6, 2024, pp. 9-15.
PMID
38953728
MeSH Terms
Humans; Disease Management; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Receptor, trkA; Thyroid Neoplasms
같은 제1저자의 인용 많은 논문 (3)
- Durability of Response With Selpercatinib in Patients With -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
- Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit.
- LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve -mutant medullary thyroid cancer.